Bicistronic adenovirus-mediated gene transfer of CTLA4Ig gene and CD40Ig gene result in indefinite survival of islet xenograft

Transplantation Proceedings

Volumn 35, Issue 8, 2003, Pages 3165-3166

  Jin, Y Z ^a   Xie, S S ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT DNA;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; HORIZONTAL GENE TRANSFER; IMMUNOGLOBULIN GENE; INTERMETHOD COMPARISON; KIDNEY CAPSULE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SURVIVAL TIME; TITRIMETRY; VIRUS RECOMBINANT; XENOGRAFT;

EID: 0345870063     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.10.064     Document Type: Article

References (6)

1. Larsen C.P. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:1996;434.
2. Kirk A.D. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 94:1997;8789.
3. He T.C. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 95:1998;2509.
4. Feng S. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig. Transplantation. 67:1999;1607.
5. Kawai T. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 6:2000;114.
6. Kirk A.D. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant. 191:2001;A223.